Cargando…

Is Early Conversion to mTOR Inhibitors Represent a Suitable Choice in Renal Transplant Recipients? A Systemic Review of Medium-term Outcomes

BACKGROUND: Immunosuppressive therapies are important parts of renal transplantation. OBJECTIVE: To assess the present literature on the effectiveness of early introduction of mTOR inhibitors with or without calcineurin inhibitors (CNI) in renal transplant recipients in terms of renal functioning an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kumar, J., Reccia, I., Kusano, T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Avicenna Organ Transplantation Institute 2017
Materias:	Systematic Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5549003/ https://www.ncbi.nlm.nih.gov/pubmed/28828166

Ejemplares similares

mTOR Inhibitors Induce Erythropoietin Resistance in Renal Transplant Recipients
por: Jefferies, Reece, et al.
Publicado: (2022)

Cancer and mTOR inhibitors in kidney transplantation recipients
por: Kao, Chih-Chin, et al.
Publicado: (2018)

Optimising the use of mTOR inhibitors in renal transplantation
por: Russ, Graeme R
Publicado: (2013)

Conversion to mTOR-Inhibitors Plus IV Immunoglobulins in Kidney-Transplant Recipients with BKV Infection: A Retrospective Comparative Study
por: Vela, Carla, et al.
Publicado: (2022)

Evaluation of quantitative changes in regulatory T cells in peripheral blood of kidney transplant recipients with skin cancer after conversion to mTOR inhibitors
por: Cegielska, Agnieszka, et al.
Publicado: (2018)

Skin cancer in solid organ transplant recipients: are mTOR inhibitors a game changer?
por: Geissler, Edward K
Publicado: (2015)

Systemic meta-analysis assessing the short term applicability of early conversion to mammalian target of rapamycin inhibitors in kidney transplant
por: Kumar, Jayant, et al.
Publicado: (2017)

Experience with the mTOR Inhibitor Everolimus in Pediatric Liver Graft Recipients
por: Wehming, Mathis, et al.
Publicado: (2023)

Conversion to mTOR-inhibitor-based immunosuppression: which patients and when?
por: Gatault, Philippe, et al.
Publicado: (2013)

Systemic and Nonrenal Adverse Effects Occurring in Renal Transplant Patients Treated with mTOR Inhibitors
por: Zaza, Gianluigi, et al.
Publicado: (2013)

mTOR-Inhibition and COVID-19 in Kidney Transplant Recipients: Focus on Pulmonary Fibrosis
por: Granata, Simona, et al.
Publicado: (2021)

Real-Life Experience of mTOR Inhibitors in Liver Transplant Recipients in a Region Where Living Donation Is Predominant
por: Sung, Pil Soo, et al.
Publicado: (2021)

Robot-Assisted Radical Prostatectomy in Renal Transplant Recipients: A Systematic Review
por: Piana, Alberto, et al.
Publicado: (2023)

The Role of mTOR Inhibitors in Liver Transplantation: Reviewing the Evidence
por: Klintmalm, Goran B., et al.
Publicado: (2014)

The impact of switching to mTOR inhibitor-based immunosuppression on long-term non-melanoma skin cancer incidence and renal function in kidney and liver transplant recipients
por: Murray, Susan L., et al.
Publicado: (2020)

mTOR Pathway and mTOR Inhibitors in Head and Neck Cancer
por: Gao, Wei, et al.
Publicado: (2012)

Long-Term Redistribution of Peripheral Lymphocyte Subpopulations after Switching from Calcineurin to mTOR Inhibitors in Kidney Transplant Recipients
por: Llinàs-Mallol, Laura, et al.
Publicado: (2020)

mTOR inhibitor versus mycophenolic acid as the primary immunosuppression regime combined with calcineurin inhibitor for kidney transplant recipients: a meta-analysis
por: Xie, Xishao, et al.
Publicado: (2015)

Non-melanoma skin cancer outcomes in kidney transplant recipients converted from calcineurin inhibitors to mTOR inhibitors: a systematic review
por: Olszewska, Berenika, et al.
Publicado: (2023)

mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
por: Zou, Zhilin, et al.
Publicado: (2020)

Clinical Implications of mTOR Expression in Papillary Thyroid Cancer—A Systematic Review
por: Derwich, Aleksandra, et al.
Publicado: (2023)

A Decade of Experience Using mTor Inhibitors in Liver Transplantation
por: Campsen, Jeffrey, et al.
Publicado: (2011)

The influence of mTOR inhibitors on immunity and the relationship to post-transplant malignancy
por: Geissler, Edward K
Publicado: (2013)

The Role of mTOR Inhibitors after Liver Transplantation for Hepatocellular Carcinoma
por: Todeschini, Letizia, et al.
Publicado: (2023)

Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors
por: Hassan, Burhan, et al.
Publicado: (2014)

Conversion therapy and suitable timing for subsequent salvage surgery for initially unresectable hepatocellular carcinoma: What is new?
por: Zhang, Ze-Feng, et al.
Publicado: (2018)

mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy
por: Tian, Tian, et al.
Publicado: (2019)

Overcoming mTOR Resistance Mutations with a New Generation mTOR Inhibitor
por: Rodrik-Outmezguine, Vanessa S., et al.
Publicado: (2016)

Predictive Value of EGFR-PI3K-AKT-mTOR-Pathway Inhibitor Biomarkers for Head and Neck Squamous Cell Carcinoma: A Systematic Review
por: de Kort, W. W. B., et al.
Publicado: (2021)

Inhibitors of mTOR in aging and cancer
por: Zhavoronkov, Alexander
Publicado: (2015)

Gerosuppression by pan-mTOR inhibitors
por: Leontieva, Olga V., et al.
Publicado: (2016)

mTOR inhibitors in cancer therapy
por: Xie, Jianling, et al.
Publicado: (2016)

mTor Inhibitors for the Treatment of Endometriosis
por: Barra, Fabio, et al.
Publicado: (2018)

Targeting ganglioneuromas with mTOR inhibitors
por: Tao, Ting, et al.
Publicado: (2021)

Overview of Research into mTOR Inhibitors
por: Mao, Beibei, et al.
Publicado: (2022)

Place of mTOR inhibitors in management of BKV infection after kidney transplantation
por: Jouve, Thomas, et al.
Publicado: (2016)

Treatment Options in Metastatic Renal Cell Carcinoma: Focus on mTOR Inhibitors
por: Pal, Sumanta Kumar, et al.
Publicado: (2010)

Therapeutic Use of mTOR Inhibitors in Renal Diseases: Advances, Drawbacks, and Challenges
por: Viana, Sofia D., et al.
Publicado: (2018)

Polymorphisms in mTOR and Calcineurin Signaling Pathways Are Associated With Long-Term Clinical Outcomes in Kidney Transplant Recipients
por: Campos-Salazar, Antony Brayan, et al.
Publicado: (2018)

Commentary: Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor
por: Renna, Maurizio
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_bltl5n462upvkbg3npe4dje6s6